Hospitals and Diagnostic Laboratories segment to dominate the Asia Pacific Liver Cancer Diagnostics Market during 2021–2028

 According to a new market research study on “Asia Pacific Liver Cancer Diagnostics Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type and End User” is expected to reach US$ 3,375.39 million by 2028 from US$ 1,902.85 million in 2021. The market is estimated to grow at a CAGR of 8.5% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific liver cancer diagnostics market along with the drivers and restraints pertaining to the market growth. Growing emergence of new technologies, surging demand for point-of-care testing, and increasing prevalence of liver cancer are the major factor driving the growth of the Asia Pacific liver cancer diagnostics market. However, extensive cost of technologically advanced liver cancer diagnostic solutions hinders the growth of Asia Pacific liver cancer diagnostics market.

The Asia Pacific liver cancer diagnostics market is segmented on the basis of type, end user, and country. Based on type, the market is segmented into laboratory tests, imaging, endoscopy, biopsy, and others. In 2021, the laboratory tests segment held a larger share of the market; and the imaging segment is expected to register a higher CAGR during the forecast period. Further based on laboratory tests, the Asia Pacific liver cancer diagnostics market is segmented into blood tests and biomarkers. In 2021, the blood tests segment held the largest market share; and the same segment is expected to register the highest CAGR in the market during the forecast period. Based on end user, the market is segmented into hospitals and diagnostic laboratories, academic and research institutes, and CRO laboratories. In 2021, the hospitals and diagnostic laboratories segment held a larger share of the market; and the same segment is expected to register a higher CAGR during the forecast period. Based on country, the Asia Pacific liver cancer diagnostics market is segmented into China, Japan, India, South Korea, Australia, and Rest of APAC. In 2021, China held the largest market share; and Japan is expected to grow at the fastest CAGR during the forecast period.

Abbott; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Illumina, Inc.; Koninklijke Philips N.V.; QIAGEN; Siemens Healthineers AG; THERMO FISHER SCIENTIFIC INC.; GE Healthcare; and Perspectum are among the leading companies in the Asia Pacific liver cancer diagnostics market. For instance, Illumina, Inc. announced Berry Oncology is overseeing China’s first and only large-scale, forward-looking cohort study of early liver cancer screening based on next-generation sequencing (NGS) technology via Illumina Technology.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com